IDH1 c.51A>G ;(p.E17=)

Variant ID: 2-209116225-T-C

NM_005896.2(IDH1):c.51A>G;(p.E17=)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.

Blood Cancer Discovery
Wang, Victoria E VE; Blaser, Bradley W BW; Patel, Ravi K RK; Behbehani, Gregory K GK; Rao, Arjun A AA; Durbin-Johnson, Blythe B; Jiang, Tommy T; Logan, Aaron C AC; Settles, Matthew M; Mannis, Gabriel N GN; Olin, Rebecca R; Damon, Lloyd E LE; Martin, Thomas G TG; Sayre, Peter H PH; Gaensler, Karin M KM; McMahon, Emma E; Flanders, Michael M; Weinberg, Vivian V; Ye, Chun J CJ; Carbone, David P DP; Munster, Pamela N PN; Fragiadakis, Gabriela K GK; McCormick, Frank F; Andreadis, Charalambos C
Publication Date: 2021-09

Variant appearance in text: IDH1: E17E
PubMed Link: 34514432
Variant Present in the following documents:
  • Main text
View BVdb publication page